EGFR and duodenal adenocarcinoma: If the response of duodenal adenocarcinoma was similar to that of colorectal cancer, angiogenesis inhibitors would be better than EGFR inhibitors for the treatment of duodenal adenocarcinoma with KRAS mutation.